Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 28/2/2020
SIETES contiene 92917 citas

 
 
<< anterior 21 a 40 de 310 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Spence D. Bad medicine: the rise of duloxetine. BMJ 2014;348:g139. [Ref.ID 97247]
23.
Smith A, Bevan D, Douglas HR, James D. Management of urinary incontinence in women: summary of updated NICE guidance. BMJ 2013;347:33-7. [Ref.ID 96263]
24. Cita con resumen
Anónimo. Mirabegron for overactive bladder syndrome. Drug Ther Bull 2013;51:90-2. [Ref.ID 96150]
25.Enlace a cita original Cita con resumen
Anónimo. MTRAC reviews - August 2013. Prescribing Advice for GPs 2013:27 de agosto. [Ref.ID 95900]
26. Cita con resumen
Anónimo. Mirabegron (Myrbetriq) for overactive bladder. Med Lett Drugs Ther 2013;55:13-5. [Ref.ID 94999]
27.Tiene citas relacionadas
Nelson HD. Menopausal hormone therapy and primary prevention. Ann Intern Med 2013;158:141. [Ref.ID 94780]
28.Tiene citas relacionadas
Schaer TM. Menopausal hormone therapy and primary prevention. Ann Intern Med 2013;158:140-1. [Ref.ID 94779]
29. Cita con resumen
Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MFR, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF, for the Pelvic Floor Disorders Network. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med 2012;367:1803-13. [Ref.ID 94025]
30. Cita con resumen
Anónimo. Fésotérodine. "Hyperactive vésicale": me-too de la toltérodine. Prescrire 2012;32:812. [Ref.ID 93972]
31. Cita con resumen
Anónimo. Mirabegron approved for overactive bladder. United States of America. WHO Drug Information 2012;26:274-5. [Ref.ID 93689]
32. Cita con resumen
Anónimo. Toxine botulique de type A et incontinence urinaire d'origine neurologique. Prescrire 2012;32:657-60. [Ref.ID 93659]
34. Cita con resumen
Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a sytematic review. Ann Intern Med 2012;156:857-60. [Ref.ID 93318]
35. Cita con resumen
Nager CW, Brubaker L, Litman HJ, Zyczynski HM, Varner RE, Amundsen C, Sirls LT, Norton PA, Arisco AM, Chai TC, Zimmern P, Barber MD, Dandreo KJ, Menefee SA, Kenton K, Lowder J, Richter HE, Khandwala S, Nygaard I, Kraus SR, Johnson HW, Lemack GE, Mihova M, Albo ME, Mueller E, Sutkin G, Wilson TS, Hsu Y, Rozanski TA, Rickey LM, Rahn D, Tennstedt S, Kusek JW, Gormley EA, for the Urinary Treatment Network. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med 2012;366:1987-97. [Ref.ID 93028]
36.
38. Cita con resumen
Anónimo. Midodrine: troubles cardiovasculaires et cutanés. Prescrire 2012;32:352. [Ref.ID 92807]
39.
Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM. The management of overactive bladder syndrome. BMJ 2012;344:38-44. [Ref.ID 92690]
40. Cita con resumen
Boudreau DM, Yu O, Gray SL, Raebel MA, Johnson J, Larson EB. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. J Am Geriatr Soc 2011;59:2069-76. [Ref.ID 91576]
Seleccionar todas
 
<< anterior 21 a 40 de 310 siguiente >>